We are conducting Open Collaboration actively to improve our research capacities

Present ~ 2016

Signed total $768m deal to license out gastroesophageal reflux treatment, Fexuprazan to US and China
Completed phase 1 trials of DWP710(stem cell COVID-19 therapy) in Indonesia
US FDA designated DWN12088 as Orphan Drug for Systemic Sclerosis and it is the second time as an orphan drug designation(ODD) since 2019
Developed COVID-19 treatment and selected for a government-sponsored project
Daewoong Pharmaceutical’s Olostar was listed in the 2020 National R&D Excellence Top 100.
Novel diabetes drug Enavogliflozin designated for expedited review for the first time in Korea and conducted a phase 3 clinical trial
Registered as a bio-pharmaceutical accelerator, and sign an MOU with Gyeongsangnam-do, Gimhae, and Inje University
Established iN Therapeutics, a drug discovery company (spun off from Daewoong Pharmaceutical)
Selected as a company to be supported by the Ministry of Food and Drug Safety (MDFS) for Quality by Design (QbD)
Independently developed botulinum toxin Nabota obtained marketing authorization in Taiwan and Brazil
Obtained halal certification for Easyef Topical Solution and Epodion through Daewoong Infion, a joint venture in Indonesia
Concluded agreements with Mexico and Brazil to export the next-gen gastroesophageal reflux disease drug Fexuprazan
Established AffyXell Therapeutics, a joint venture specializing in cellular therapeutics, with the British biotech company Avacta
Acquired the international standard ISO 9001 certification for a quality management system (QMS)
Received the Minister’s Award (Ministry of Science and ICT) as an institute of outstanding research note management
Completed phase-3 clinical trial on Fexuprazan, a next-generation drug for gastroesophageal reflux
Awarded by the government as an outstanding innovative pharmaceutical company
DWN12088, a new drug for pulmonary fibrosis, designated as an orphan drug by the USFDA
Urusa 300mg obtained indication for prevention of postgastrectomy cholelithiasis, being the first in the world
Officially launched Jeuveau, an internally developed botulinum toxin, in the US
Launched Olomax, a compound of three agents (olmesarta, rosuvastatin and amlopidine)
Phase-3 clinical trial result of Nabota in the US published in an SCI-grade international journal
DWN12088, a new drug for pulmonary fibrosis, selected for the inter-governmental support project
Internally developed botulinum toxin approved by USFDA, being the first in Asia
Nabota obtained indication for eye wrinkles as the first botulinum toxin in Korea
DWP14012, a new drug for gastroesophageal reflux, selected for inter-governmental support project
Completed construction of the Daewoong Bio Center
Meropenem Inj, an antibiotic, approved by the USFDA

2015 ~ 2011

Olostar won the Technology Award for new drug development at the 16th Korea New Drug Award (KNDA)
Began joint development in the field of antibody through M&A with HanAll BioPharma
Received a Prime Minister Citation in the science and technology category of the Korea New Growth Management Awards
Won the Technology Award for new drug development at the 15th Korea New Drug Award (KNDA)
Nabota selected as a World Class Product of Korea by the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Trade-Investment Promotion Agency (KOTRA)
Released Nabota, a botulinum toxin, in Korea
Released Olostar, a new drug compound of olmesartan and rosuvastatin
Won the 2013 Innovative Pharmaceutical Company Award
Caretropin Pen won the 2011-2012 World Star Award
Selected for World Class 300, a global business development project
Selected as an Innovative Pharmaceutical Company
Caretropin Inj. received the Minister’s Award
(Ministry of Knowledge Economy)

2010 ~ 2001

Easyef acquired the International Nonproprietary Name (INN) certified by the World Health Organization (WHO) as the first in the world
CoenzymeQ10 won the Minister’s Award (Ministry of Health and Welfare) at the Outstanding Technology Contest of the Health Industry Technologies Exposition Korea
CoenzymeQ10 won the Jang Yong-shil Award
Released Luphere, an anticancer agent
Succeeded in developing CoenzymeQ10, being the second in the world
Easyef Topical Solution won second prize at the Korea New Drug Award
(Korea Drug Research Association: KNDA)
Easyef Topical Solution awarded as one of 100 Outstanding Patented Products
Released Easyef Topical Solution, Korea’s first new bio-pharmaceutical drug
Acquired the KT (Korea Good Technology) mark for Easyef

2000 ~ Founded

Won Outstanding Achievement Award (Korean Intellectual Property Office) for the patented technology of Easyef
Received the Iron Tower Order of Industrial Service Merit in the science and technology category on the 1st Science Day
Acquired the first genetic engineering patent in Korea
Established Daewoong Central R&D Institute
Established Subsidiary Pharmaceutical Research Center